Aviva’s Ligand Pharmaceuticals LGND Stock Holding History

Aviva’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,378	Closed	-$622K	–	923
2024 Q2	$622K	Buy	7,378 +1,402	+23%	+$112K	﹤0.01%	741
2024 Q1	$437K	Buy	+5,976	New	+$441K	﹤0.01%	884

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Aviva's LGND Position: Q3 2024 in Review

Aviva sold out of Ligand Pharmaceuticals (LGND) in Q3 2024, closing a stake of 7,378 shares — an estimated $622K sold.

Aviva first reported a position in LGND in Q1 2024 and held it in 2 quarters. The position peaked at $622K in Q2 2024. 243 funds tracked by Wall St. Rank hold LGND as of Q3 2024.

Aviva reported no remaining Ligand Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Aviva sold 7,378 Ligand Pharmaceuticals shares in Q3 2024, an estimated $622K.
Aviva first reported a position in Ligand Pharmaceuticals in Q1 2024 and held it in 2 quarters.
Aviva's Ligand Pharmaceuticals position peaked at $622K in Q2 2024.
243 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2024.

Based on Aviva's 13F filing for Q3 2024, filed 14 Nov 2024.